Exelixis (EXEL) investor relations material

Capital allocation and strategic priorities

• Focus on efficient capital allocation, prioritizing investments based on data and evolving competitive landscape.

• Flexibility to shift between share buybacks and R&D investments, especially in promising early-stage assets.

• CABO-driven cash flows support ongoing investments and allow for dynamic capital deployment over the next several years.

• Emphasis on maximizing shareholder value by building franchise molecules that improve patient care.

• No fixed approach; capital is allocated to best opportunities as data and market conditions evolve.

Product lifecycle management and commercial strategy

• CABO remains a priority with a runway of 4.5–5 years, with no plans to reduce focus as zanza approaches approval.

• Strategy aims to avoid cannibalizing CABO’s value while expanding the portfolio with zanza.

• Commercial execution is strong, with recent launches showing rapid adoption among key opinion leaders.

• Ongoing efforts to maintain and grow CABO’s market share, especially in competitive oncology segments.

• Sales force and commercial infrastructure are well-positioned to support both CABO and upcoming zanza launches.

R&D and clinical development outlook

• Zanza is viewed as the next major growth driver, with significant investment in controlled, data-driven development.

• Multiple pivotal trials for zanza are underway, with top-line data from STELLAR-304 expected in the second half of the year.

• Clinical strategy includes targeting both clear cell and non-clear cell indications, leveraging combination therapies.

• Emphasis on rigorous trial design and partner selection to maximize efficacy and safety.

• STELLAR-316 trial in CRC leverages MRD positivity for patient selection and aims for rapid enrollment in the U.S.